文献速递生殖医学

双刺激与单刺激后行新鲜胚胎移植在年轻低预后患者中的比较:DUOSTIM-fresh随机对照试验

Double versus single stimulation in young low prognosis patients followed by a fresh embryo transfer: a randomized controlled trial (DUOSTIM-fresh).
PubMed 文献 · Hum Reprod · 2024-06-06

这项单中心随机对照优效性试验纳入120例年轻(<40岁)低预后(AMH<1.2 ng/ml)患者,比较双刺激后新鲜胚胎移植(DUOSTIM fresh)与单刺激后新鲜胚胎移植,发现双刺激组优质囊胚数显著更多(均数差0.81,95%CI 0.12-1.49),而新鲜胚胎移植后的临床结局无显著差异。

要点

  • DUOSTIM fresh较单刺激显著增加优质囊胚数(均数差0.81,95%CI 0.12-1.49)。
  • 双刺激与单刺激的鲜胚移植率(62.3% vs 51.9%)和持续妊娠率(24.5% vs 22.2%)无显著差异。
  • 作者认为,鉴于对移植率和妊娠结局的改善尚不明确,行双刺激的决策应谨慎评估。

核心结论

  • 在年轻低预后患者中,与单刺激相比,DUOSTIM fresh可获得显著更多的优质囊胚,且不损害新鲜胚胎移植结局。
  • 作者认为,鉴于双刺激能否改善胚胎移植率和妊娠结局仍不明确,行双刺激的决策应谨慎评估,并需累积活产率的结果。

研究设计与样本

  • 随机、对照、单中心、优效性临床试验,比较双刺激周期与单刺激周期后行新鲜胚胎移植。
  • 2020年10月至2022年10月共纳入120例女性,按1:1分配。
  • 纳入标准:年龄<40岁、低预后(抗苗勒管激素<1.2 ng/ml),就诊于Dexeus大学医院生殖医学科。
  • 主要结局为获得的优质囊胚数;次要结局包括新鲜胚胎移植结果(临床妊娠、流产)。

主要发现

  • 共分析107例患者,研究组(DUOSTIM fresh)53例,对照组(单刺激)54例。
  • DUOSTIM fresh组优质囊胚数显著高于单刺激组(均数差0.81,95%CI 0.12-1.49)。
  • 行胚胎移植的周期百分比两组相当(双刺激62.3% vs 单刺激51.9%)。
  • 新鲜胚胎移植后临床结局无显著差异,持续妊娠率DUOSTIM fresh组24.5% vs 常规IVF组22.2%。
  • 不同刺激周期比较(A:黄体期DUOSTIM fresh,B:卵泡期DUOSTIM fresh,C:单刺激)的卵巢反应无显著差异,成熟卵母细胞数均值(SD)分别为A:3.3(2.9)、B:3.4(3.4)、C:3.5(2.9)。

临床怎么用

  • 作者认为,尽管DUOSTIM fresh较单刺激获得更多囊胚,但行双刺激的决策应谨慎评估,因其能否改善胚胎移植率和妊娠结局仍不明确,且需累积活产率的结果。

局限性

  • 研究样本量按检测优质囊胚均数差异计算,因此次要结局(胚胎移植率和临床妊娠率)的结果应作为探索性发现谨慎解读,值得未来进一步研究。
  • 双刺激能否改善胚胎移植率和妊娠结局仍不明确,需累积活产率的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does double stimulation, followed by a fresh embryo transfer (DUOSTIM fresh) give a higher number of good-quality blastocysts as compared with a single stimulation in young low prognosis patients? SUMMARY ANSWER: Compared to single stimulation, DUOSTIM fresh leads to a significantly higher number of good quality blastocysts, without hindering fresh embryo transfer outcomes. WHAT IS KNOWN ALREADY: DUOSTIM (ovarian stimulation both in the follicular and luteal phase of the same cycle) is an innovative strategy to retrieve a higher number of oocytes in a shorter time frame, thus it is particularly appealing for poor ovarian responders. Three current limitations of dual stimulation are: (i) it is unclear whether outcomes of the second (luteal) wave result from the second stimulation, or a carry-over effect from previous follicular stimulation; (ii) the desynchronization between endometrium and ovaries and, (iii) lack of robust evidence. No previous studies explored DUOSTIM starting from the luteal phase, and with a fresh embryo transfer (DUOSTIM fresh). STUDY DESIGN, SIZE, DURATION: This study is a randomized, controlled, single-center, superiority clinical trial comparing two different ovarian stimulation protocols: a double stimulation cycle versus a single stimulation cycle followed by fresh embryo transfer. The primary outcome was the number of good quality blastocysts obtained, while secondary outcomes included results from fresh embryo transfer (clinical pregnancy, miscarriage). A total of 120 women were enrolled in this study between October 2020 and October 2022, with a 1:1 allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Only young (<40 years old) low prognosis (anti-Müllerian hormone <1.2 ng/ml) patients were recruited in the Reproductive Medicine Department of Dexeus University Hospital. In the investigational group, DUOSTIM fresh, the first stimulation was initiated in the luteal phase (Day 18-21 cycle) followed by a second stimulation 5 days post first oocyte retrieval, initiated in the follicular phase and a fresh embryo transfer of the best blastocyst generated (first or second cycle). The control group performed a follicular phase single stimulation cycle with a fresh embryo transfer. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 107 patients were analyzed, 53 in the investigational (DUOSTIM fresh) and 54 in the control arm (single stimulation). DUOSTIM fresh resulted in a significantly higher number of good quality blastocysts as compared to single stimulation (difference of mean 0.81, 95% CI 0.12-1.49). The mean percentage of cycles with embryo transfer was comparable (62.3% and 51.9%, respectively for double versus single stimulation). No significant differences were found for clinical outcomes following fresh embryo transfer with an ongoing pregnancy rate of 24.5% for DUOSTIM fresh versus 22.2%, for conventional IVF. Of interest comparisons between different stimulation cycles (A: luteal-phase DUOSTIM fresh, B: follicular-phase DUOSTIM fresh, and C: single stimulation) did not demonstrate any significant difference in terms of ovarian response with the mean (SD) number of mature oocytes being (A: 3.3 (2.9), B: 3.4 (3.4), and C: 3.5 (2.9), respectively). LIMITATIONS, REASONS FOR CAUTION: Study sample size was calculated to detect differences on the mean number of good quality blastocysts. Therefore, results for secondary outcomes (embryo transfer rates and clinical pregnancy rates) should be interpreted with caution as exploratory findings that deserve future investigations. WIDER IMPLICATIONS OF THE FINDINGS: Although DUOSTIM fresh results in a higher number of blastocysts as compared with a single stimulation in young low prognosis patients, the decision of performing dual stim should be evaluated with caution, considering that whether this may improve embryo transfers rate and pregnancy outcomes is still unclear. Results on cumulative-live-birth-rate are warranted. STUDY FUNDING/COMPETING INTEREST(S): The study was an investigator-initiated study supported by an unrestricted grant by Organon. N.P.P. has received grants from Merck Serono, Organon, Ferring Pharmaceutical, Theramex, and Besins Healthcare. N.P.P. has received consulting fees from Merck Serono, Organon, Besins Healthcare, and IBSA. N.P.P. has received honoraria for lectures from Merck Serono, Organon, Theramex, Roche Diagnostics, IBSA, Besins Healthcare, and Ferring. A.R. has received Research grants, honoraria for lectures from Merck Serono, MSD/Organon, Ferring Pharmaceuticals, Besins International, IBSA, Guerbet. The other authors declare that there is no conflict of interest to disclose with respect to the content of this article. TRIAL REGISTRATIO NUMBER: NCT04446845. TRIAL REGISTRATION DATE: 25 June 2020. DATE OF FIRST PATIENT’S ENROLMENT: 30 October 2020.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Racca A, Rodriguez I, Garcia S, et al. Double versus single stimulation in young low prognosis patients followed by a fresh embryo transfer: a randomized controlled trial (DUOSTIM-fresh). Hum Reprod. 2024. PMID: 38845190. doi:10.1093/humrep/deae104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。